Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Delayed Data from NSDQ)

$17.66 USD

17.66
1,533,637

+0.46 (2.67%)

Updated Nov 8, 2024 04:00 PM ET

Pre-Market: $17.80 +0.14 (0.79%) 8:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?

Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.

Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow

Bristol-Myers' (BMY) third-quarter 2023 earnings and sales beat estimates as Opdivo and new products offset losses due to oncology drug Revlimid's generic erosion.

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in the third quarter of 2023, partially offset by declining swine product sales.

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?

On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.

What's in Store for Canopy Growth (CGC) in Q2 Earnings?

In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.

Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View

Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.

InMode (INMD) to Post Q3 Earnings: What's in the Cards?

InMode (INMD) is likely to register growth in Q3, backed by strong consumable and service revenues and ongoing global expansion.

CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?

CVS Health (CVS) Q3 revenues will likely benefit from growth in specialty pharmacy and brand inflation and increased prescription and front store volume.

Dynavax (DVAX) to Report Q3 Earnings: Will It Beat Estimates?

On Dynavax's (DVAX) third-quarter earnings call, investors' focus is likely to be on the sales performance of the company's hepatitis B vaccine, HEPLISAV-B.

Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?

Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. Pipeline updates are expected over the earnings call.

Labcorp (LH) to Report Q3 Earnings: What's in the Cards?

Labcorp's (LH) third-quarter 2023 performance is likely to have witnessed strength in the Diagnostics Laboratories base business.

IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?

IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.

Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards?

Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products.

Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale

Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.

Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B

Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.

Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback

Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.

Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study

Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.

Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain

Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.

Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering

Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.

Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now

Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Acadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI